State Street’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-827,956
| Closed | -$1.89M | – | 4360 |
|
|
2024
Q2 | $1.89M | Buy |
827,956
+666,850
| +414% | +$2.55M | ﹤0.01% | 3336 |
|
|
2024
Q1 | $696K | Hold |
161,106
| – | – | ﹤0.01% | 3562 |
|
|
2023
Q4 | $491K | Hold |
161,106
| – | – | ﹤0.01% | 3643 |
|
|
2023
Q3 | $232K | Hold |
161,106
| – | – | ﹤0.01% | 3896 |
|
|
2023
Q2 | $401K | Sell |
161,106
-37,060
| -19% | -$101K | ﹤0.01% | 3751 |
|
|
2023
Q1 | $531K | Buy |
198,166
+18,430
| +10% | +$88.6K | ﹤0.01% | 3726 |
|
|
2022
Q4 | $976K | Sell |
179,736
-1,438,645
| -89% | -$12.1M | ﹤0.01% | 3561 |
|
|
2022
Q3 | $20.2M | Buy |
1,618,381
+1,476,175
| +1,038% | +$16.9M | ﹤0.01% | 2217 |
|
|
2022
Q2 | $702K | Sell |
142,206
-3,534,608
| -96% | -$19.6M | ﹤0.01% | 3712 |
|
|
2022
Q1 | $27.9M | Sell |
3,676,814
-624,799
| -15% | -$5.93M | ﹤0.01% | 2154 |
|
|
2021
Q4 | $43.9M | Sell |
4,301,613
-81,999
| -2% | -$1.04M | ﹤0.01% | 1902 |
|
|
2021
Q3 | $58.8M | Buy |
4,383,612
+1,612,565
| +58% | +$26.3M | ﹤0.01% | 1690 |
|
|
2021
Q2 | $60.8M | Buy |
2,771,047
+40,111
| +1% | +$891K | ﹤0.01% | 1697 |
|
|
2021
Q1 | $65.7M | Buy |
2,730,936
+151,117
| +6% | +$3.51M | ﹤0.01% | 1544 |
|
|
2020
Q4 | $46.4M | Buy |
2,579,819
+214,560
| +9% | +$3.21M | ﹤0.01% | 1685 |
|
|
2020
Q3 | $27.3M | Buy |
2,365,259
+1,004,346
| +74% | +$16.6M | ﹤0.01% | 1843 |
|
|
2020
Q2 | $33M | Sell |
1,360,913
-11,801
| -0.9% | -$195K | ﹤0.01% | 1710 |
|
|
2020
Q1 | $15.1M | Sell |
1,372,714
-2,614
| -0.2% | -$48.8K | ﹤0.01% | 2029 |
|
|
2019
Q4 | $36.4M | Buy |
1,375,328
+227,433
| +20% | +$5.32M | ﹤0.01% | 1741 |
|
|
2019
Q3 | $26.1M | Sell |
1,147,895
-188,065
| -14% | -$5.93M | ﹤0.01% | 1889 |
|
|
2019
Q2 | $41M | Buy |
1,335,960
+133,599
| +11% | +$2.81M | ﹤0.01% | 1611 |
|
|
2019
Q1 | $20M | Sell |
1,202,361
-9,978
| -0.8% | -$189K | ﹤0.01% | 2040 |
|
|
2018
Q4 | $23.2M | Buy |
1,212,339
+392,737
| +48% | +$14.7M | ﹤0.01% | 1878 |
|
|
2018
Q3 | $42.9M | Sell |
819,602
-123,948
| -13% | -$6.76M | ﹤0.01% | 1649 |
|
|
2018
Q2 | $41M | Buy |
943,550
+721,655
| +325% | +$30.9M | ﹤0.01% | 1606 |
|
|
2018
Q1 | $8.22M | Buy |
221,895
+105,036
| +90% | +$2.8M | ﹤0.01% | 2556 |
|
|
2017
Q4 | $2.32M | Buy |
116,859
+69,241
| +145% | +$1.49M | ﹤0.01% | 3132 |
|
|
2017
Q3 | $1.18M | Buy |
+47,618
| New | +$879K | ﹤0.01% | 3344 |
|
State Street's GTHX Position: Q3 2024 in Review
State Street sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 827,956 shares — an estimated $1.89M sold.
State Street first reported a position in GTHX in Q3 2017 and held it in 28 quarters. The position peaked at $65.7M in Q1 2021. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- State Street reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- State Street sold 827,956 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $1.89M.
- State Street first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2017 and held it in 28 quarters.
- State Street's G1 Therapeutics, Inc. Common Stock position peaked at $65.7M in Q1 2021.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on State Street's 13F filing for Q3 2024, filed 14 Nov 2024.